期刊
INTERFACE FOCUS
卷 9, 期 2, 页码 -出版社
ROYAL SOC
DOI: 10.1098/rsfs.2018.0077
关键词
prostate cancer; diagnostics; biomarkers; lectins; glycans; prostate-specific antigen
类别
资金
- Slovak Scientific Grant Agency VEGA [2/0137/18, 2/0090/16]
- Slovak Research and Development Agency [APVV 17-0300]
- ERC Proof of Concept grant [825586]
- Innovative Training Network [813120]
- ERDF [26240120007]
- European Research Council (ERC) [825586] Funding Source: European Research Council (ERC)
The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据